Read Gene

Read Gene FCF Margin

The Free Cash Flow Margin of Read Gene (RDG.WA) as of Nov 5, 2026 is -2.90 %. In the previous year, Free Cash Flow Margin was 13.01 % — a change of -122.29% (lower).

FCF Margin

-2.90 %

YoY

-122.29%

Last updated:

Free Cash Flow Margin of Read Gene is 2025 -2.90 % . Free Cash Flow Margin of Read Gene was 2024 13.01 % . It decreases by -122.29% lower compared to the previous year.

The Read Gene FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-7.99 PLN
Jan 1, 2019
-60.62 PLN
Jan 1, 2020
24.80 PLN
Jan 1, 2021
0.71 PLN
Jan 1, 2022
4.61 PLN
Jan 1, 2023
-11.66 PLN
Jan 1, 2024
13.01 PLN
Jan 1, 2025
-2.90 PLN
The Read Gene FCF Margin history
YEARFCF MarginYoY
-2.90 %-122.29%
13.01 %-211.66%
-11.66 %-353.03%
4.61 %+545.01%
0.71 %-97.12%
24.80 %-140.91%
-60.62 %+658.27%
-7.99 %-38.40%
-12.98 %-1,017.49%
1.41 %-102.38%
-59.54 %-79.98%
-297.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Free Cash Flow Margin of Read Gene is -2.90 % in 2025.

Free Cash Flow Margin of Read Gene changed from 13.01 % to -2.90 %, representing a -122.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Read Gene since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Read Gene

All Key Metrics — Read Gene